Clinicopathologic factors associated with false negative FDG–PET in primary breast cancer
- 365 Downloads
The present study was aimed to determine the clinicopathologic factors that predict false negative (FN) PET results in these patients.
A total of 116 breast lesions in 111 patients (pre-menopausal 45; perimenopausal 15; post-menopausal 51) with known or suspicious of breast cancer who underwent FDG–PET scans for staging, were included in this study. The median age was 52±11 years (range 32–79 years). All PET studies results were correlated with follow-up surgical pathology results. A cut off value of 2.5 was considered for positive or negative PET results. Univariate and multivariate analyses were performed to identify factors associated with FN results.
Of 116 breast lesions, 85 were malignant and 31 were benign on histopathology. Of the 85 malignant lesions, 41 were true positive (TP) and 44 were FN. Among the 31 benign lesions, 30 were true negative and one was false positive. There was significant difference in the tumor size (p=0.003) and tumor grade (p=0.001) in patients with TP and FN PET results. Multivariate logistic regression demonstrated that tumor size (≤10 mm) and low tumor grade were independently associated with FN results. No significant relationship of FN PET results was found with age, menopausal status, tumor type, c-erbB-2, estrogen and progesterone receptors, sentinel lymph node or distant metastasis, parenchymal density and multifocality of primary breast tumor.
In present study, tumor size and tumor grade are independent factors that predict FDG–PET results. Smaller tumors (≤10 mm) and low-grade tumors are strong predictor of FN FDG–PET results.
Keywordsbreast cancer clinicopathologic factors false negative FDG–PET
Unable to display preview. Download preview PDF.
This work was supported by Public Health Services Research Grant M01-RR00040 from NIH. Rakesh Kumar, MD, was financially supported by UICC (International Union Against Cancer) Geneva, Switzerland under ACSBI fellowship.
- 2.Surveillance, Epidemiology, and End Results (SEER) Program (www. seer. cancer. gov) SEER Statistics Database: Incidence – SEE (1973–2000), National Cancer Institute, DCCPS, Surveillance Research Program, Cancer Statistics BranchGoogle Scholar
- 3.Rosenberg RD, Hunt WC, Williamson MR, Gilliland FD, Wiest PW, Kesely CA, Key CR, Linver MN., (1998). Effects of age, breast density, ethnicity, and estrogen replacement therapy on screening mammographic sensitivity and cancer stage at diagnosis: review of 183,134 screening mammograms in Albuquerque, New Mexico Radiology 209:511–18PubMedGoogle Scholar
- 4.Baines CJ, Miller AB, Wall C, McFarlane DV, Simor IS, Jong R, Shapiro BJ, Audet L, Petitclerc M, Ouimet-Oliva D, 1986 Sensitivity and specificity of first screen mammography in the Canadian National Breast Screening Study: a preliminary report from five centersRadiology. 160:295–98PubMedGoogle Scholar
- 18.Bos R, van Der Hoeven JJ, van Der Wall E, van Der Grope P, van Diest PJ, Comans EF, Joshi U, Semenza GL, Hoekstra OS, Lammertsma AA, Molthoff CF, 2002 Biologic correlates of (18)fluorodeoxyglucose uptake in human breast cancer measured by positron emission tomography. J Clin Oncol 20:379–87CrossRefPubMedGoogle Scholar
- 23.Borgwardt L, Hojgaard L, Carstensen H, Dose J, Weber W, Laubenbacher C, Romer W, Janicke F, Schwaiger M, 2005 Increased fluorine-18 2-fluoro-2-deoxy-D-glucose (FDG) uptake in childhood CNS tumors is correlated with malignancy grade: a study with FDG positron emission tomography/magnetic resonance imaging coregistration and image fusion. J Clin Oncol 23:3030–37CrossRefPubMedGoogle Scholar
- 24.Crippa F, Seregni E, Agresti R, Chiesa C, Pascali C, Bogni A, Decise D, De Sanctis V, Greco M, Daidone MG, Bombardieri E., 1998 Association between [18F]fluorodeoxyglucose uptake and postoperative histopathology, hormone receptor status, thymidine labelling index and p53 in primary breast cancer: a preliminary observation. Eur J Nucl Med 25:1429–34CrossRefPubMedGoogle Scholar